112 related articles for article (PubMed ID: 9816268)
41. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
[TBL] [Abstract][Full Text] [Related]
42. Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients.
Boffetta P; Fichtinger-Schepman AM; Weiderpass E; van Dijk-Knijnenburg HC; Stoter G; van Oosterom AT; Keizer HJ; Fosså SD; Kaldor J; Roy P
Anticancer Drugs; 1998 Feb; 9(2):125-9. PubMed ID: 9510497
[TBL] [Abstract][Full Text] [Related]
43. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours.
Steiner H; Müller T; Gozzi C; Akkad T; Bartsch G; Berger AP
BJU Int; 2006 Aug; 98(2):349-52. PubMed ID: 16626306
[TBL] [Abstract][Full Text] [Related]
44. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
Mardiak J; Fuchsberger P; Lakota J; Sálek T; Sycová-Milá Z; Drahokoupilová M; Baláz M; Koza I
Neoplasma; 2000; 47(4):239-43. PubMed ID: 11043829
[TBL] [Abstract][Full Text] [Related]
45. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
46. Determination of cisplatin in blood compartments of cancer patients.
Mustonen R; Hemminki K; Alhonen A; Hietanen P; Kiilunen M
IARC Sci Publ; 1988; (89):329-32. PubMed ID: 3198217
[TBL] [Abstract][Full Text] [Related]
47. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
Ma J; Verweij J; Planting AS; de Boer-Dennert M; van Ingen HE; van der Burg ME; Stoter G; Schellens JH
Br J Cancer; 1995 Mar; 71(3):512-7. PubMed ID: 7880732
[TBL] [Abstract][Full Text] [Related]
48. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
[TBL] [Abstract][Full Text] [Related]
49. DNA adducts induced by platinum drug chemotherapeutic agents in human tissues.
Poirier MC; Shamkhani H; Reed E; Tarone RE; Gupta-Burt S
Prog Clin Biol Res; 1992; 374():197-212. PubMed ID: 1620704
[No Abstract] [Full Text] [Related]
50. [Platinum concentrations in human tissue after administration of cisplatin].
Tochigi T; Ono K; Yoshikawa K; Hoshi S; Orikasa S; Imai Y
Gan To Kagaku Ryoho; 1988 Feb; 15(2):269-75. PubMed ID: 3341789
[TBL] [Abstract][Full Text] [Related]
51. Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adducts.
Gill I; Muggia FM; Terheggen PM; Michael C; Parker RJ; Kortes V; Grunberg S; Christian MC; Reed E; den Engelse L
Ann Oncol; 1991 Feb; 2(2):115-21. PubMed ID: 2054312
[TBL] [Abstract][Full Text] [Related]
52. Alkylating agents and platinum: is clinical resistance simply a tumor cell phenomenon?
Reed E
Curr Opin Oncol; 1991 Dec; 3(6):1055-9. PubMed ID: 1843107
[TBL] [Abstract][Full Text] [Related]
53. The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
Carcinogenesis; 1988 Oct; 9(10):1909-11. PubMed ID: 2458857
[TBL] [Abstract][Full Text] [Related]
54. The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.
Welters MJ; Braakhuis BJ; Jacobs-Bergmans AJ; Kegel A; Baan RA; van der Vijgh WJ; Fichtinger-Schepman AM
Ann Oncol; 1999 Jan; 10(1):97-103. PubMed ID: 10076728
[TBL] [Abstract][Full Text] [Related]
55. Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study.
Hjelle LV; Gundersen PO; Oldenburg J; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Bremnes RM; Haugnes HS
Anticancer Res; 2015 Mar; 35(3):1619-25. PubMed ID: 25750319
[TBL] [Abstract][Full Text] [Related]
56. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
Schellens JH; Ma J; Planting AS; van der Burg ME; van Meerten E; de Boer-Dennert M; Schmitz PI; Stoter G; Verweij J
Br J Cancer; 1996 Jun; 73(12):1569-75. PubMed ID: 8664132
[TBL] [Abstract][Full Text] [Related]
57. [Coordinated platinum compounds in experimental and clinical oncology].
Lobanova EA; Kozlova MD; Singin AS; Serebriakov NG
Med Radiol (Mosk); 1984 Jun; 29(6):59-63. PubMed ID: 6376996
[No Abstract] [Full Text] [Related]
58. Biomonitoring of cisplatin-DNA adducts in cancer patients receiving cisplatin chemotherapy.
Reed E; Ozols RF; Fasy T; Yuspa SH; Poirier MC
Prog Clin Biol Res; 1986; 209B():247-52. PubMed ID: 3749082
[No Abstract] [Full Text] [Related]
59. Oxaliplatin-DNA adduct formation in white blood cells of cancer patients.
Pieck AC; Drescher A; Wiesmann KG; Messerschmidt J; Weber G; Strumberg D; Hilger RA; Scheulen ME; Jaehde U
Br J Cancer; 2008 Jun; 98(12):1959-65. PubMed ID: 18506148
[TBL] [Abstract][Full Text] [Related]
60. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy.
Tothill P; Klys HS; Matheson LM; McKay K; Smyth JF
Eur J Cancer; 1992; 28A(8-9):1358-61. PubMed ID: 1515251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
